Abstract: The present invention is related to the discovery of several single nucleotide polymorphisms (SNPs) and/or mutations in the Alpha-2-Macroglobulin gene (A2M), which are risk factors for Alzheimer's Disease (AD). More specifically, aspects of the invention concern nucleic acids corresponding to the A2M gene or fragments thereof, which contain one or more of the SNPs and/or mutations described herein, peptides or proteins encoded by said nucleic acids, antibodies to said peptides or proteins and methods of making said compositions, diagnostic methods, methods of data analysis, and pharmaceutical discovery and preparation methods.
Type:
Application
Filed:
June 26, 2003
Publication date:
April 8, 2004
Applicants:
Neurogenetics, Inc., The General Hospital Corporation
Inventors:
Kenneth David Becker, Gonul Velicelebi, Xin Wang, Lars Bertram, Aleister J. Saunders, Rudolph E. Tanzi
Abstract: Genetic markers associated with Alzheimer's disease are provided. Also provided are methods of determining the presence or absence in a subject of one or more polymorphisms associated with Alzheimer's disease and methods of determining the level of risk for Alzheimer's disease in a subject. Further provided are nucleic acid compositions and kits for use in determining the presence or absence in a subject of one or more polymorphisms associated with Alzheimer's disease and kits for determining the level of risk for Alzheimer's disease in a subject.
Type:
Application
Filed:
October 25, 2002
Publication date:
September 11, 2003
Applicant:
Neurogenetics, Inc.
Inventors:
Rudolph E. Tanzi, Kenneth David Becker, Gonul Velicelebi, Kathryn J. Elliott, Xin Wang, Lars Bertram, Aleister J. Saunders, Deborah Lynne Blacker